Prostate-specific antigen

There are 231 papers on prostate-specific antigen in aging research: 31 trials and 126 observational studies in people, 3 in animals, 59 reviews. The newest story, Nov 21, 2026: “Inherited risk score adds to prostate cancer blood test”.

Biomarker

231 papers study it60 more mention it70 findings

MeSH

26 new papers in 30 daysSee all 291 papers on prostate-specific antigen

At a glance

Higher prostate-specific antigen is linked with prostate cancer incidence and mortality in human cohorts, including previously screened older men without a prostate cancer diagnosis. Testosterone increases levels in human trials, although a trial in men with hypogonadism finds no clear effect. Reviews describe noncancer influences and variation between assays and laboratories.

70 findings in 56 papers from 1992 to 2026, 9 of them since April 2026

“We found three time points indicating changes in the chronological trends of PSA.”
Chronological Trends of PSA Levels at Diagnosis in Population-based Prostate Cancer Data 2004-2021, a Time Period of Drastic Changes in Screening Guidelines: Potential Implications in Prostate Cancer DiagnosisJournal of registry management2025
  • Human trial31
  • Humans126
  • Animals3
  • In silico7

Interventions

10

Testosterone

upin humans6no changein humans2downin humans1

9 studies
  1. Testosterone increases prostate-specific antigen in humans (0.15 ng/mL at 12 months (95% CI, 0.08-0.21)).

    Human trial21.8 (14.2) months in the TRT group and 21.6 (14.0) months in the placebo groupmalesn = 5,204

  2. Testosterone increases prostate-specific antigen in humans (hypogonadism and CVD or increased CVD risk).

    Human trialhypogonadism and CVD or increased CVD risktopical 1.62% gelmean 21.8 monthsmalesn = 5,204

  3. Testosterone increases prostate-specific antigen in humans.

    Human trial3 yearsmales

  4. Testosterone increases prostate-specific antigen in humans (testosterone deficiency) (0.65 ± 0.1 to 1.35 ± 0.1 ng/ml (mean ± SEM); remained within normal range).

    Human trialtestosterone deficiencytestosterone enanthate200 mg every second week1.5–6 yearsmalesn = 30

  5. Testosterone showed no clear effect on prostate-specific antigen in humans (hypogonadism).

    Human trialhypogonadismtestosterone cypionate200 mg biweekly12 monthsmales

  6. Testosterone is linked with higher prostate-specific antigen in humans (from 1.12 ± 1.11 μg/L to 1.26 ± 1.22 μg/L).

    Humans1% testosterone gelserum12 monthsmales

  7. Testosterone was not clearly linked with prostate-specific antigen in humans (symptomatic androgen deficiency).

    Humanssymptomatic androgen deficiencyup to 20 yearsmales

  8. Testosterone decreases prostate-specific antigen in humans (hypogonadism or low testosterone level) (MD=-0.05, 95%CI [-0.08, -0.02]).

    Reviewhypogonadism or low testosterone level

  9. Testosterone increases prostate-specific antigen in humans (age-related male hypogonadism) (difference in means = 0.154, 95% CI 0.069 to 0.238, P < 0.001).

    Reviewage-related male hypogonadism3 to 12 monthsmales

  10. Testosterone increases prostate-specific antigen in humans.

    Reviewweeklyup to 2 yearsmales

More on Testosterone

Green tea

no changein humans1downin humans1

1 study
  1. Green tea was not clearly linked with prostate-specific antigen in humans (younger age groups).

    Humansyounger age groupsmalesn = 415

  2. Green tea is linked with lower prostate-specific antigen in humans (older age groups).

    Humansolder age groupsmalesn = 415

More on Green tea

Early detection

downin humans1

1 study
  1. Early detection is linked with lower prostate-specific antigen in humans (at diagnosis) (median PSA 8.2 vs. 11.0 ng/ml).

    Humansat diagnosismalesn = 20,253

More on Early detection

Walking

no changein humans1

1 study
  1. Walking showed no clear effect on prostate-specific antigen in humans (low-risk, localized PCa).

    Human triallow-risk, localized PCa16 weeksmales

More on Walking

Nordic walking

downin humans1

1 study
  1. Nordic walking decreases prostate-specific antigen in humans.

    Human trial12 monthsmales

More on Nordic walking

Finasteride

downin humans1−40%

1 study
  1. Finasteride decreases prostate-specific antigen in humans (benign prostatic hyperplasia) (approximately 40 %).

    Human trialbenign prostatic hyperplasia1-yearmalesn = 79

More on Finasteride

Cholecalciferol

no changein humans1

1 study
  1. Cholecalciferol showed no clear effect on prostate-specific antigen in humans (healthy Black men) (-0.004 ng/mL (P = 0.92) for each additional 1,000 U/d).

    Human trialhealthy Black men1,000, 2,000, or 4,000 U/d3 monthsmalesn = 105

More on Cholecalciferol

17-alpha-estradiol

downin human cells1

1 study
  1. 17-alpha-estradiol inhibits prostate-specific antigen in human cells (induced by cyproterone acetate or dihydrotestosterone).

    Cellsinduced by cyproterone acetate or dihydrotestosteroneLNCaP cells

More on 17-alpha-estradiol

Soy isoflavones + curcumin

downin human cells1

1 study
  1. Soy isoflavones + curcumin decreases prostate-specific antigen in LNCaP cells.

    Cellsin LNCaP cells

More on Soy isoflavones + curcumin

Testosterone enanthate

upin humans1

1 study
  1. Testosterone enanthate increases prostate-specific antigen in humans.

    Human trialtestosterone enanthateserum100 mg weekly3 monthsmalesn = 13

More on Testosterone enanthate

Effects

2

Mortality

downin humans1

1 study
  1. Prostate-specific antigen decreases mortality in humans (PC management).

    ReviewPC management

Cognitive function

no changein humans1

1 study
  1. Prostate-specific antigen was not clearly linked with cognitive function in humans (before radical prostatectomy).

    Humansbefore radical prostatectomy

Upstream

4

Type 2 diabetes

downin humans1

1 study
  1. Type 2 diabetes is linked with lower prostate-specific antigen in humans (median 0.92 ng/mL vs 1.1 ng/mL, p = 0.01).

    Humansmalesn = 100

More on Type 2 diabetes

Prostate cancer

upin humans1

1 study
  1. Prostate cancer is linked with higher prostate-specific antigen in humans (symptomatic referred patients).

    Humanssymptomatic referred patientsmales

More on Prostate cancer

Age

upin humans1

1 study
  1. Age is linked with higher prostate-specific antigen in humans (referred on a PCa diagnostic pathway) (mean 0.17 ng/mL/year, r2 = 0.09 vs 0.13).

    Humansreferred on a PCa diagnostic pathwaymales

Albumin

downin humans1OR 0.82

1 study
  1. Albumin is linked with lower prostate-specific antigen in humans (adjusting for age) (OR = 0.82).

    Humansadjusting for agemales

More on Albumin

Associations

33

Age

upin humans6

6 studies
  1. Age is associated with prostate-specific antigen in humans (African men with prostate cancer).

    HumansAfrican men with prostate cancermalesn = 1,907

  2. Age is associated with prostate-specific antigen in humans (healthy men with no known prostate pathologies).

    Humanshealthy men with no known prostate pathologiesprostate10 yearsmalesn = 1,037

  3. Age is associated with prostate-specific antigen in humans (r = 0.31, p = 0.002).

    Humansmalesn = 100

  4. Age is associated with prostate-specific antigen in humans (r = 0.219, 95% CI 0.103-0.330).

    Humansmalesn = 1,536

  5. Age is associated with prostate-specific antigen in humans (healthy health screening) (P = 0.0005).

    Humanshealthy health screeningserummalesn = 86,728

  6. age is associated with prostate-specific antigen in humans (r = 0.274, p<0.001).

    Humansserummalesn = 213,986

Prostate cancer

upin humans6HR 2.01

6 studies
  1. Prostate-specific antigen is associated with prostate cancer in humans (increasing PSA levels) (91% vs. 38% at PSA levels ≥ 20 μg/L).

    Humansincreasing PSA levelsprostate1 yearmalesn = 10,777

  2. Prostate-specific antigen is linked with a higher risk of prostate cancer in humans (doubling of total PSA in joint model) (HR 2.01, 95% CI 1.99-2.02).

    Humansdoubling of total PSA in joint modelmales

  3. Prostate-specific antigen predicts prostate cancer in humans (asymptomatic men undergoing PSA testing) (observed-to-expected ratio > 1).

    Humansasymptomatic men undergoing PSA testingmalesn = 414,731

  4. Prostate-specific antigen predicts prostate cancer in humans (4.780 ng/mL).

    Humansmales

  5. Prostate-specific antigen predicts prostate cancer in fragile men with a life expectancy of over 15 years.

    Reviewin fragile men with a life expectancy of over 15 yearsmales

  6. Prostate-specific antigen predicts prostate cancer in humans (frail men with more than 15 years life expectancy).

    Reviewfrail men with more than 15 years life expectancymales

More on Prostate cancer

Prostate cancer mortality

upin humans2HR 5

2 studies
  1. Prostate-specific antigen is linked with a higher risk of prostate cancer mortality in humans (initial PSA level <3 ng/ml) (HR 5.0, 95% CI 3.1-8.1).

    Humansinitial PSA level <3 ng/mlmedian follow-up of 17.8 yrmalesn = 20,268

  2. Prostate-specific antigen is linked with a higher risk of prostate cancer mortality in humans (localised prostate cancer) (sdHR 7.13).

    Humanslocalised prostate cancer12.5 yearsmalesn = 204

Inter-assay and inter-laboratory variability

mixedin humans1

1 study
  1. inter-assay and inter-laboratory variability is associated with prostate-specific antigen in humans (PSA differences exceeding 20%).

    Review

Non-cancer-related factors

mixedin humans1

1 study
  1. non-cancer-related factors are associated with prostate-specific antigen in humans (Independent of malignancy) (30 factors associated with elevation; 15 associated with reduction).

    ReviewIndependent of malignancy

Prostate cancer aggressiveness

upin humans1

1 study
  1. Prostate-specific antigen is associated with prostate cancer aggressiveness in humans (African men with prostate cancer; assessed by Gleason score and tumor stage).

    HumansAfrican men with prostate cancer; assessed by Gleason score and tumor stagemalesn = 1,907

Body mass index

downin humans1

1 study
  1. Body mass index is associated with prostate-specific antigen in humans (African men with prostate cancer).

    HumansAfrican men with prostate cancermalesn = 1,907

More on Body mass index

Body mass index

upin humans1

1 study
  1. Prostate-specific antigen is associated with body mass index in humans (Elevated versus normal age-specific PSA concentrations).

    HumansElevated versus normal age-specific PSA concentrationsmalesn = 5,325

Lower urinary tract symptoms

upin humans1

1 study
  1. Prostate-specific antigen is associated with lower urinary tract symptoms in humans (Elevated PSA concentrations).

    HumansElevated PSA concentrationsmalesn = 5,325

More on Lower urinary tract symptoms

Erectile dysfunction

upin humans1

1 study
  1. Prostate-specific antigen is associated with erectile dysfunction in humans (Elevated PSA concentrations).

    HumansElevated PSA concentrationsmalesn = 5,325

More on Erectile dysfunction

All 33

Funding

4 grants since 2019

National Cancer Institute$4.9MStanford University$157KGouvernement du Canada | Canadian Institutes of Health ResearchCA$17.5K

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 3Jan 2026: 21Feb 2026: 15Mar 2026: 15Apr 2026: 8May 2026: 4Jun 2026: 3Jul 2026: 6Aug 2026: 15Sep 2026: 9Oct 2026: 17Nov 2026: 18134 papers in 12 months
medRxiv

Inherited risk score adds to prostate cancer blood test

High versus low scores were linked to a hazard ratio—a measure of relative rates over time—of 3.32 for both treatment and cancer spread.High versus low scores were linked to a hazard ratio—a measure of relative rates over time—of 3.32 for both treatment and cancer spread.

Preprint: cohort study of 428,512 peopleProstate cancer
Cancer

Prostate screening trade-offs worsen with age in models

Models estimated 2.7–3.1 overdiagnoses per prostate cancer death prevented at 72 versus 4.5–5.1 at 76 in men without other illnesses.Models estimated 2.7–3.1 overdiagnoses per prostate cancer death prevented at 72 versus 4.5–5.1 at 76 in men without other illnesses.

Computational studyInterventions

See all 291 papers on prostate-specific antigen